GVR Report cover Facial Injectable Market Size, Share & Trends Report

Facial Injectable Market Size, Share & Trends Analysis Report By Product (Collagen, Hyaluronic Acid, Botulinum Toxin Type A, Calcium Hydroxylapatite, Polymer Fillers), By Application (Aesthetic, Therapeutic), By Region, And Segment Forecasts 2022 - 2030

  • Report ID: GVR-1-68038-849-7
  • Number of Pages: 172
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2020
  • Industry: Healthcare

Report Overview

The global facial injectable market size was valued at USD 16.1 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 9.1% from 2022 to 2030. A growing focus on physical appearance among consumers has led to an increased demand for facial injectables in recent years. Increasing awareness regarding minimally invasive procedures due to various beauty campaigns being organized by key players in the market is also a driving factor for market growth. The ongoing COVID-19 pandemic has increased the time spent on video calls. Known as the ‘Zoom Boom’, several adults are becoming more aware of their appearance. This has increased demand for cosmetic surgeries, with Botox being one of the most popular products preferred.

U.S. facial injectable market size, by product, 2020 - 2030 (USD Billion)

Patients are also opting for cosmetic surgeries owing to ease of recovery while staying at home. Thus, the market has witnessed a spike during the pandemic and this trend is expected to boost further. The presence of well-established key players like Allergan, Sinclair Pharma, Galderma with a comprehensive injectable fillers portfolio treating a broad range of skin indications like wrinkles, pigmentation, plumping of lips, scars, restoring facial fullness as well as enhancing facial contours is expected to drive the demand for facial injectable procedures thereby boosting market revenue. Increasing social media exposure, rising effectiveness, and approvals for facial injectable as well as the escalating desire among the population to look aesthetically appealing and young is expected to drive the market during the forecast period.

Minimally invasive surgeries are rapidly replacing invasive surgeries. For instance, according to the American Society of Plastic Surgeons (ASPS), in the U.S., nearly 18 million minimally invasive and surgical cosmetic products were performed in 2020, out of which nearly 16 million products were minimally invasive. Thus, the increasing adoption of minimally invasive surgeries, coupled with the availability of a wide range of such treatment options, is driving the market growth. According to the International Society of Aesthetic Plastic Surgery (ISAPS), the U.S. was ranked 1st in terms of non-surgical products performed at a global level. Of these, injectables such as botulinum toxin and hyaluronic acid were among the most popular products performed. The country is backed by advanced treatment options and has the highest number of surgeons at a global level, with over 7,000 plastic surgeons as of 2019. These factors support market growth.

COVID19 impact: 51% increase in demand is expected in the coming years

Pandemic Impact

Post COVID Outlook

The imposition of national lockdowns and subsequent closure of clinics has negatively impacted aesthetic practices. According to a survey by Hamilton Fraser, in 2020, nearly 99.78% of participants reported that their practice was affected by the COVID-19 pandemic, with around 80.51% of aesthetic practitioners reporting the closure of clinics, around 67.28% reporting a reduction in revenue while about 63.31% reporting reduction in inquiries.

Post covid, increasing focus on digital consultations is expected to be one of the priorities of practitioners to ensure patient engagement.

AbbVie reported a loss in Botox sales in Q2 of 2020 due to the COVID-19 pandemic. AbbVie Inc acquired Allergan in May 2020.

According to a study conducted by Cynosure, nearly 62% of the practitioners were confident about their business revenue returning to the pre-Covid level within 12 months of the lifting of impositions


Incidents of adverse reactions to the Moderna COVID-19 vaccine in patients with dermal fillers have created fear amongst patients.


In June 2020, Allergan Aesthetics, a subsidiary of AbbVie Inc. (U.S.), received FDA approval for JUVÉDERM VOLUMA XC for the augmentation of the chin region in adults over the age of 21. Apart from this, in 2019, FDA approved, Jeuveau, which is similar to Botox, however, available at a lower cost compared to Botox. The product is found to be effective in reducing wrinkles. Signs of aging, include wrinkles and sagging of the skin due to low facial elasticity, dark spots, etc., and start appearing between 25 and 30 years of age and become more prominent from 30 to 65 years of age. Thus, the presence of a large population susceptible to various signs of aging is boosting the demand for facial injectable medicine globally.

The aesthetic industry witnessed a significant setback due to the COVID-19 pandemic in the initial quarters of 2020. However, many dermatologists reported that COVID-19 may act as a springboard that will drastically increase patient footfall post-pandemic. The survey conducted by Cynosure in June 2020 reported that the majority of the surveyed population showed a high willingness to opt for in-office non-invasive treatments. Even during the pandemic Botox and soft tissue fillers remained the most popular minimally invasive procedures in the U.S. This indicates that even though the facial injectable market faced a slight decline in the first half of 2020, it is going to recover strongly during the forecast period.

Product Insights

The botulinum toxin type A segment dominated the market and accounted for the largest revenue share of 55.2% in 2021. Middle-aged women are increasingly opting for fillers and injectables including the popular, Botox to reverse the signs of aging. The Hyaluronic Acid (HA) segment is projected to witness the fastest CAGR of 9.6% during the forecast period. It is known for its ability to store moisture in the skin, thus making the skin look healthier. HA has a moisture-binding characteristic that helps enhance and maintain the vital moisture responsible for the plumpness of the facial skin. Cosmetic-grade HA has a low molecular weight that facilitates deep penetration of the product in the epidermis, which further helps by retaining water in the cells and releases antioxidants that delay the aging process. According to the International Society of Aesthetic, around 4,053,016 procedures for hyaluronic dermal injections were performed globally in 2020.

Application Insights

The aesthetics segment dominated the market and accounted for the largest revenue share of 70.5% in 2021. This growth is owing to the increasing use of facial injectables for aesthetic procedures such as facial lines, wrinkles on the face, and lip lines, to name a few. Factors like growing awareness about aesthetic procedures and rising disposable income are expected to boost the market growth. An increase in the use of facial injectables for parentheses lines, wrinkles on the face, lip lines, lip augmentation, lip border restoration, perioral lines, and crow’s feet lines are expected to assist in market growth.

Global facial injectable market share, by application, 2021 (%)

The growing interest in physical appearance along with an increase in disposable income among the middle-class population in developing countries such as India is expected to boost demand for facial injectables for aesthetic purposes in the coming years. The therapeutic segment is expected to register a double-digit CAGR over the forecast period. This is attributed to increasing applications of facial injectables in the treatment of blepharospasm, strabismus or crossed eyes, Meige's syndrome, Oromandibular Dystonia (OMD), Hemifacial Spasms (HFS), and focal hyperhidrosis.

Regional Insights

North America dominated the market and accounted for the largest revenue share of more than 41.0% in 2021. This growth is owing to the large geriatric population in the U.S. and Canada is anticipated to propel the demand for facial injectables over the forecast period. According to the American Society of Plastic Surgeons (ASPS), the growth in rates of cosmetic surgery products from the year 2000 to 2018 was compared.  It was observed that the use of Botox injections increased by 845%. Thus, North America is expected to be a key revenue generator for facial injectables in the coming years.

Asia Pacific market is projected to witness the highest CAGR of 10.3% during the forecast period. The region is backed by countries such as India, Australia, and South Korea. Growing focus on the physical appearance in these developing countries is expected to play a key role in the demand for facial injectable treatment. India is projected to be the fastest-growing during the forecast period.

Key Companies & Market Share Insights

The key players are focusing on growth strategies, such as enhancements in the existing technologies, geographical expansion, product launches, and product approvals. Recently, in February 2020, Sinclair Pharma offered distribution partnership rights of Sculptra (poly-I-Iatic acid injectable) to Galderma SA specifically in Europe. Also in 2019, one of the key players, Allergan, had launched a TV ad campaign for its brand, Botox Cosmetics for millennials. According to the American Academy of Facial Plastic and Reconstructive Surgery, in the past five years, Botox injections have increased by 22% among 22- to 37-year-olds, focusing on which the product is being launched by the company. Some of the prominent players in the facial injectable market include:

  • Ipsen

  • Merz Pharma

  • Suneva Medical, Inc.

  • Medytox Inc.

  • Sinclair Pharma

  • Bloomage BioTechnology Corporation Limited

  • Anika Therapeutics Inc.

  • Prollenium Medical Technologies

  • Galderma

  • Allergan, Inc.

  • Nestle Skin Health

  • Zimmer Biomet

  • Abbvie Inc

  • SciVision Biotech Inc

  • Croma-Pharma GmbH

  • Revance Therapeutics Inc

  • Bioplus Co. Ltd

  • Bioaxis Pharmaceuticals

Facial Injectable Market Report Scope

Report Attribute


Market size value in 2022

USD 17.4 billion

Revenue forecast in 2030

USD 35.0 billion

Growth Rate

CAGR of 9.1% from 2022 to 2030

Base year for estimation


Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, application, end user, generation, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Switzerland; Netherland; Belgium;  Japan; China; India; Australia; South Korea; Thailand; Malaysia; Singapore; Indonesia; Philippines; Brazil; Mexico; Argentina; Colombia; Chile; South Africa; Saudi Arabia; UAE; Israel; Turkey

Key companies profiled

Ipsen; Merz Pharma; Suneva Medical, Inc.; Medytox Inc.; Sinclair Pharma; Bloomage BioTechnology Corporation Limited; Anika Therapeutics Inc.; Prollenium Medical Technologies; Galderma; Allergan, Inc; Nestle Skin Health; Zimmer Biomet; Abbvie Inc; SciVision Biotech Inc; Croma-Pharma GmbH; Revance Therapeutics Inc; Bioplus Co. Ltd; Bioaxis Pharmaceuticals

Customization scope

Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional, and segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global facial injectable market report on the basis of product, application, end user, generation, region:

  • Product Outlook (Revenue, USD Million, 2018 - 2030)

    • Collagen

    • Hyaluronic Acid (HA)

    • Botulinum Toxin Type A

    • Calcium Hydroxylapatite (CaHA)

    • Polymer Fillers

      • Polymethylmethacrylate beads (PMMA Microspheres)

      • Poly-L-Lactic Acid (PLLA)

  • Application Outlook (Revenue, USD Million, 2018 - 2030)

    • Aesthetics

      • Facial Line Correction

      • Lip Augmentation

      • Face Lift

      • Acne Scar Treatment

      • Lipoatrophy Treatment

      • Others

    • Therapeutics

  • End User Outlook (Revenue, USD Million, 2018 - 2030)

    • Hospitals

    • Dermatology Clinics

    • Others

  • Generation Outlook (Revenue, USD Million, 2018 - 2030)

    • Gen X

    • Boomer

    • Millennials

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

      • Switzerland

      • Netherland

      • Belgium

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • Thailand

      • South Korea

      • Malaysia

      • Singapore

      • Indonesia

      • Philippines

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

      • Chile

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

      • Israel

      • Turkey

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon